PD-L1在非小细胞肺癌中的研究进展

Research Progress of PD-L1 in Non-Small Cell Lung Cancer

摘要: 非小细胞肺癌(non-small cell lung cancer, NSCLC)是起源于支气管黏膜、支气管腺体及肺泡上皮的一类肺恶性肿瘤，发病率及死亡率均较高；治疗方案包括手术、放化疗、中药、靶向药物治疗、免疫治疗等，但大多数早期阶段的NSCLC患者因缺乏临床表现错过了最佳的手术治疗时机。应用免疫检查点抑制剂(ICIs)改善了晚期NSCLC患者的生存率，程序性死亡受体配体1 (PD-L1)是研究焦点，但它们并非没有挑战，只有少数NSCLC患者对ICIs有反应，这说明需要更好的免疫治疗。了解免疫治疗的耐药机制、明确PD-L1的表达调控机制将为提高PD-1/PD-L1抑制剂治疗的效果提供帮助。

Abstract: Non-small cell lung cancer (NSCLC) is a kind of lung malignant tumor originating from bronchial mucosa, bronchial glands and alveolar epithelium, with high morbidity and mortality. Treatment options include surgery, radiotherapy and chemotherapy, traditional Chinese medicine, targeted drug therapy, immunotherapy, etc. However, most patients with early-stage NSCLC have missed the optimal opportunity for surgical treatment due to lack of clinical manifestations. The application of immune checkpoint inhibitors (ICIs) has improved survival in patients with advanced NSCLC, and programmed death receptor ligand 1 (PD-L1) is the focus of research, but they are not without challenges, and only a small number of NSCLC patients respond to ICIs, illustrating the need for better immunotherapy. Understanding the mechanism of drug resistance in immunotherapy and clarifying the regulatory mechanism of PD-L1 expression will provide help to improve the thera-peutic effect of PD-1/PD-L1 inhibitors.